Using eClinicalWorks® Capabilities

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

To Include BLENREP in Order Sets, Send Ophthalmic Exam Notifications, and Monitor Patients' Results

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Notable requirements of the BLENREP REMS include the following:

Prescribers must be certified in the BLENREP REMS by enrolling and completing training. Prescribers must counsel patients receiving BLENREP on the risk of ocular toxicity, the need for monitoring via ophthalmic exams before each dose, and provide patients with the BLENREP REMS Patient Guide. Patients must be enrolled in the BLENREP REMS and adhere to monitoring. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling and must obtain authorization prior to dispensing. Wholesalers and distributors must distribute BLENREP only to certified healthcare settings.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

About This Guide

This electronic health record (EHR) guide is intended to help healthcare providers (HCPs) use eClinicalWorks® capabilities to facilitate accurate prescribing for BLENREP. It includes steps and examples for adding BLENREP to Order Sets, automating notifications for HCPs and patients about REMS requirements, the need for ophthalmic exams and complete blood count (CBC) tests as directed in the USPI, and customizing Flowsheets to capture and monitor patients' overall ophthalmic exam results grading which can be used to inform BLENREP treatment decisions in line with the USPI.

This guide does not constitute guidance for treatment or medical advice. It is the HCP's responsibility to select a treatment based on their independent medical judgment and the needs of each individual patient.

The examples and instructions listed in this guide are based on the most recent version of eClinicalWorks. Locations, illustrations, and terminology are subject to change with system updates. This guide is meant to serve as an overview only and should not replace detailed instructions provided to you by your internal or external EHR support resources. GSK makes no claims or warranties about the applicability or appropriateness of this information. This guide has not been reviewed or endorsed by eClinicalWorks. GSK does not endorse or recommend any EHR system.

Use the links in the table of contents below or the tabs on each page to navigate this guide.

Table of Contents

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Updating an Order Set to Include BLENREP

When new information or data become available, oncology practices may update or create Order Sets that include administration instructions as well as necessary tests such as ophthalmic exams and REMS requirements (i.e., completed and submitted Patient Status Form before each dose of BLENREP and obtaining authorization to dispense for all doses). Order Sets help care teams facilitate care by grouping together clinical actions that will be administered to a patient during multiple encounters over a specific time frame.

Prescribers must be certified in the BLENREP REMS by enrolling and completing training at www.BLENREPREMS.com. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling at www.BLENREPREMS.com and must obtain authorization prior to dispensing BLENREP. If the practice has an existing Order Set for multiple myeloma and is certified in the BLENREP REMS, BLENREP can be added as a treatment option.

NOTE: *The specific Order Set components listed below are for illustrative purposes only.*

Steps for Updating an Existing Order Set

1. Navigate to **Menu** > **EMR** > **Order Set Administration**.
2. From the Order Set dropdown options, select either **Community** or **Practice Order Sets**.
3. Search for and select the **Order Set** to be updated.
4. Click the **Update** button.
5. Modify the **Order Set Description**, **Measure**, **diagnosis/trigger**, **age filter/trigger**, and **gender trigger** as appropriate.
6. Click **OK**.
7. Click the **Add** button.
8. The **Manage Orders** screen displays.
9. Search for and select **BLENREP**.
10. Click **OK**.
11. Follow the same process to add appropriate labs, referrals, follow-up, and other orders as aligned to REMS requirements in their respective sections.



Illustrative example of adding medication to Order Set (recreated from eClinicalWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Ocular Toxicity

BLENREP causes ocular toxicity, defined as changes in the corneal epithelium and changes in BCVA based on ophthalmic exam (including slit lamp exam), or other ocular adverse reactions as defined by the CTCAE.

In DREAMM-7, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 in 77% of patients. The most common ocular toxicities (>25%) were reduction in BCVA (89%) and corneal exam findings (86%) based on ophthalmic exam findings, blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%), and eye pain (33%).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Order Set to Include BLENREP

Order Sets help care teams facilitate care by grouping together clinical actions that will be administered to a patient during multiple encounters over a specific time frame.

The following steps provide an overview of the process for creating a new multiple myeloma Order Set to include BLENREP.

Steps for Creating a New Order Set

1. Navigate to **Menu** > **EMR** > **Order Set Administration**.
2. Click New to open the **New Order Set** box.
3. Add **Order Set Description**.
4. Add **Order Set Measure** if appropriate.
5. Click **OK**.



Illustrative example of creating New Order Set (recreated from eClinicalWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ocular toxicity based on ophthalmic exam findings was reported as Grade 2 in 9% of patients, Grade 3 in 56% of patients, and Grade 4 in 21% of patients. The median time to onset of the first Grade 2 to 4 ophthalmic exam findings was 43 days (range: 15 to 611 days). The median duration of all Grade 2 to 4 ophthalmic exam findings was 85 days (range: 5 to 813 days). Patients experienced a median of 3 episodes (range: 1 to 11 episodes) of ocular toxicity based on ophthalmic exam findings. Of the patients with Grade 2 to 4 ophthalmic exam findings, 42% had improvement of the last event to Grade 1 or better; 25% had resolution of the last event based on return to baseline or normal ophthalmic exam findings.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Order Set to Include BLENREP (cont.)

Steps for Creating a New Order Set (cont.)

6. Click the **Add** button to the far right of the medications section.
7. The **Manage Orders** screen displays.
8. Search for and select **BLENREP**.
9. Click **OK**.

Illustrative example of Order Search results to add medication to Order Set (recreated from eClinicalWorks)

10. Follow the same process to add appropriate labs, referrals, follow-up, and other orders as aligned to REMS requirements in their respective sections.



Illustrative example of adding labs to Order Set (recreated from eClinicalWorks)

Include the BLENREP REMS Eye Care Professional Exam Form available at **www.BLENREPREMS.com** as part of the BLENREP Order Set. The form should be completed by the patient's optometrist or ophthalmologist and sent (via eFax, Fax, EMR, or by the patient) to the oncologist at the close of the patient's eye exam to give the oncologist time to determine appropriate treatment dosing prior to administration of BLENREP. If supported, work with your EHR IT team to add the form as a custom document.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

The most commonly reported corneal exam findings included superficial punctate keratopathy, microcyst-like deposits, epithelial changes, and haze. Cases of corneal ulcer, including cases with infection, have been reported and should be managed promptly by an eye care professional.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Patient Alerts

This workflow allows HCPs to draft and set up Patient Clinical Decision Support System (CDSS) Alerts that are delivered to the patient via portal, voice, or text message. By adding Patient Alerts to a BLENREP Order Set, patients who are prescribed BLENREP will receive a patient portal message with a reminder to complete requirements prior to administration of BLENREP, including patient enrollment in the BLENREP REMS to document that they were counseled and agree to adhere to ophthalmic monitoring, required ophthalmic exams, completed BLENREP REMS Eye Care Professional Exam Form, etc.

Steps for Creating CDSS Alerts for Patients Prescribed BLENREP

eClinicalWorks® does not support the ability to automatically send patient messages outside of the context of Health Maintenance and Appointment Reminders.

Patient Messages can be created by a staff member to remind the patient of BLENREP-related follow-up activity using the Messenger feature. If functionality allows, this language may be customized depending on if the patient is receiving a dose of BLENREP or a subsequent dose.



Illustrative example of Message to be sent to patient (recreated from eClinicalWorks)



Illustrative example of Messenger access via Patient Hub (recreated from eClinicalWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

A reduction in BCVA to 20/50 or worse in at least one eye occurred in 69% of patients, including 29% who experienced a change in BCVA to 20/100 or worse, and 12% who experienced a change in BCVA to 20/200 or worse. Of the patients with reduced BCVA to 20/50 or worse in at least one eye, 61% had resolution of the last event to baseline or better. Of the patients with reduced BCVA to 20/100 or worse, 57% had resolution of the last event. Of the patients with reduced BCVA to 20/200 or worse, 48% had resolution of the last event.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating Automated HCP Inbox Messages

eClinicalWorks® allows HCPs to draft and set up silent notifications called Inbox Messages. These Inbox Messages could include a reminder to verify prescriber REMS certification and patient REMS enrollment, complete a BLENREP REMS Eye Care Professional Exam Form, submit a Patient Status Form before each dose of BLENREP, obtain authorization to dispense, or to follow up with patients prior to upcoming infusions to ensure that they have completed their required ophthalmic exams and CBC tests. Additionally, an Inbox Message may be used to remind HCPs about ordering labs or checking REMS requirements such as prescriber certification, patient enrollment, dispensing healthcare setting certification, completed and submitted Patient Status Form, authorization code prior to dispensing, etc.

Steps for Creating a Group Inbox Message

eClinicalWorks refers to Inbox Messages as Action Alerts. Action Alerts are manual reminders and can be created by a staff member to prompt the HCP of BLENREP-related activity. Action Alerts can be assigned to specific staff members and scheduled with a due date.

Action Alerts are viewable in the DRTLA (Documents, Referrals, Telephone encounters, Labs, and Actions) tab.



Illustrative example of BLENREP Action Alert in DRTLA tab (recreated from eClinicalWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ophthalmic exams (including slit lamp exam and BCVA assessment) should be conducted by an eye care professional, such as an ophthalmologist or optometrist, at baseline, before each dose of BLENREP, promptly for new or worsening symptoms, and as clinically indicated. Perform baseline exam within 4 weeks prior to the first dose. Perform each follow-up exam within 10 days prior to the next planned dose. All effort should be made to schedule the exam as close to BLENREP dosing as possible. Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less and resume at same or reduced dose or permanently discontinue based on severity.

Counsel patients to promptly inform their healthcare provider of any ocular symptoms. Counsel patients to use preservative-free artificial tears at least 4 times a day starting with the first infusion and continuing until the end of treatment, and to avoid wearing contact lenses for the duration of therapy. Bandage contact lenses may be used under the direction of an eye care professional.

Changes in visual acuity may be associated with difficulty for driving and reading. Counsel patients to use caution when driving or operating machinery.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade

Flowsheets are templates used for documentation and can be customized to capture the patient's ophthalmic exam results (conducted by either optometrists or ophthalmologists) before administration of BLENREP. Storing exam results within a Flowsheet can provide clinicians with an aggregated view of a patient's eye health and any vision changes over time. To enable this customization, a discrete data element (DDE) must first be created to define and track the ocular adverse reaction severity grade.

Steps for Adding a DDE for Tracking Ocular Adverse Reaction Severity Grade in Ophthalmic Exams

1. Navigate to **Patient Lookup** > **Select test patient** > **Access Progress Note**.
2. Navigate to **EXAM** hyperlink.
3. Select the **Ophthalmology Folder** in **Exam**.
4. Click **Custom** to build the Structure field.
5. Click **Add**.
6. Add **Property Name**.
7. Click **OK**.
8. Check the box to note as **structured "S"**.
9. Click **OK**.
10. Click in the **Observation** field to create the **components** of the ophthalmic exam.
11. Click **Custom** at the bottom of the screen.
12. Select **ADD** to create the field for the ophthalmic exam grade to track.
13. Select **Type** of response: Structured, numeric.

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade (cont.)

Steps for Adding a DDE for Tracking Ocular Adverse Reaction Severity Grade in Ophthalmic Exams (cont.)

14. Select **Customize Structured Text**.
15. Click **OK**.
16. In **Names**, add values for each ocular adverse reaction severity grade by clicking the ✚.
    a. Ensure the Grades listed correspond to the listed severity grades for Ophthalmic Exam Findings as outlined in the Prescribing Information
17. Click **OK**.
18. Click **Save** to save the added **Structured Text**.



Illustrative example of Structured Text recorded as an Observation in the General Exam tab (recreated from eClinicalWorks)

Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings[1]	
Grade 1	Continue treatment at current dosage.
Grade 2	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 3	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 4	Consider permanent discontinuation of BLENREP. If continuing treatment, withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. For patients previously on 2.5 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 1 as per Table 1. For patients previously on 1.9 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 2. If recurrent Grade 4 ocular toxicity is experienced, permanently discontinue BLENREP.

For more information on grading definitions and dose modifications for ocular toxicity and non-ocular adverse reactions, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Thrombocytopenia

Thrombocytopenia of any grade occurred in 100% of patients in DREAMM-7.

Grade 2 thrombocytopenia occurred in 10% of patients, Grade 3 in 29% of patients, and Grade 4 in 45% of patients. Clinically significant bleeding (Grade ≥2) occurred in 7% of patients with concomitant low platelet levels (Grade 3 or 4).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade (cont.)

Steps for Creating an Ophthalmic Exam Flowsheet to Document Ocular Adverse Reaction Severity Grade

1. Follow this navigation path: **eCW MENU** > **EMR** > **FLOWSHEET MANAGER**.
2. Click **...** (ellipsis button) to add the Name/Title of the Flowsheet to be created.
3. Click **OK** to add.
4. Click **OK** to edit fields.
5. Enter General Information:
   a. **Flowsheet Name:** Create a name in line with this parameter, such as *"Ophthalmic Exam Ocular Adverse Reaction Severity"*
   b. **Category:** Create a name for this category such as *"Ophthalmic Exam"*
6. Add **Parameters: Name and Type**.
7. Choose **Associated Item** for the type.
8. **Add item group**; it is recommended that this is the same as the **Type**.
9. Check **Display in Header**.
10. Click **OK** to save.
11. Add the **Name** of the structured data set to track, such as Ophthalmic Exam Ocular Adverse Reaction Severity Grade.
12. Set **Options** for scores to be documented when the ophthalmic exam is saved under **Exam**.
13. Select Type **Structured**.



Illustrative example of Flowsheet Settings to add structured data (recreated from eClinicalWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Thrombocytopenia (cont.)

Monitor complete blood cell counts at baseline and periodically during treatment as clinically indicated. Withhold or reduce the dose of BLENREP based on severity.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade (cont.)

Steps for Creating an Ophthalmic Exam Flowsheet to Document Ocular Adverse Reaction Severity Grade (cont.)

14. Click the **...** (ellipsis button) to associate the item.
15. Choose the **Exam section** under the SECTION dropdown.
16. Select the **Category**, for example, use Ophthalmology.
17. Select the **Path** to track, for example, use Ophthalmic Exam Ocular Adverse Reaction Severity Grade.
18. Click **Save** to save the Flowsheet.



Illustrative example of Flowsheet showing Ophthalmic Exam Ocular Adverse Reaction Severity Grade (recreated from eClinicalWorks)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Embryo-fetal Toxicity

Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F [MMAF]) and it targets actively dividing cells.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating an Auto Text to View or Document Ocular Adverse Reaction Severity Grade

An Auto Text phrase, or Macro, can be created to insert documented grading based on ophthalmic exam results into visit notes. Auto Text are shortcuts that insert predefined text into patient notes, discharge instructions, or other documentation using an abbreviated phrase. By typing a period (.) followed by the phrase, the predefined text associated with that phrase is automatically inserted.

Steps for Creating a New Auto Text

1. From the eCW Main Menu icon, navigate to **EMR** tab > **Miscellaneous Configuration Options** > **Configure Macros/Smart Notes** > **Macros** tab.
2. In **Configure Macros/Smart Notes**, click the plus sign to create a new Macro.
3. Input the **Macro Name**.
4. Input the **Macro Shortcut**.
   a. Note: Only alphanumeric characters are allowed
5. Enter the **Macro Text**.
6. Click **Share it with other users** checkbox.
7. Click **OK** to save.
8. Repeat steps 2-7 to create one macro for each Ocular Adverse Reaction Severity Grade in line with the USPI.



Illustrative example of configuring Macro (recreated in eClinicalWorks)

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common adverse reactions (≥20%) with BLENREP in combination with bortezomib and dexamethasone are reduction in BCVA, corneal exam findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, upper respiratory tract infection, hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract and COVID-19.

The most common Grade 3 or 4 (≥10%) laboratory abnormalities are decreased platelets, decreased lymphocytes, decreased neutrophils, increased gamma-glutamyl transferase, decreased white blood cells, and decreased hemoglobin.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

Reference: 1. BLENREP. Prescribing Information. GSK; 2025.

PMUS-BLMBRGD250008 October 2025
Produced in USA.

BLENREP belantamab mafodotin-blmf for injection 70 mg | GSK